Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 27.52% | 8.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.52% | 8.76% | |||
| Cost of Revenue | 52.66% | 56.37% | |||
| Gross Profit | 21.06% | 0.86% | |||
| SG&A Expenses | 37.41% | 10.75% | |||
| Depreciation & Amortization | 31.61% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 44.76% | 10.60% | |||
| Operating Income | 16.74% | 7.65% | |||
| Income Before Tax | -146.06% | 6.84% | |||
| Income Tax Expenses | -6.84% | 9.94% | |||
| Earnings from Continuing Operations | -180.81% | 6.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -180.81% | 6.09% | |||
| EBIT | 16.74% | 7.65% | |||
| EBITDA | 17.83% | 6.95% | |||
| EPS Basic | -180.49% | 9.83% | |||
| Normalized Basic EPS | 14.45% | 10.60% | |||
| EPS Diluted | -184.15% | 7.52% | |||
| Normalized Diluted EPS | 19.44% | 8.44% | |||
| Average Basic Shares Outstanding | 0.39% | -3.40% | |||
| Average Diluted Shares Outstanding | -3.81% | -1.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||